Long-acting injectable lenacapavir continues to show promising …
WEBSep 26, 2024 · WHO welcomes the latest findings from the PURPOSE-2 trial on long-acting injectable lenacapavir (LEN) for HIV prevention. An interim analysis, announced on 12 September 2024, demonstrated the drug’s remarkable efficacy in preventing HIV.
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced …
WEBSep 12, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.
Twice-yearly shot proves successful at preventing HIV infection …
WEBJul 24, 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
An injectable HIV-prevention drug is highly effective - NBC News
WEBThrilled over the news Thursday that lenacapavir was 89% more effective at preventing HIV than daily oral preventive medication among gay, bisexual and transgender people, plus previous...
Twice-a-year injection reduced risk of HIV infection by 96%, drug …
WEBSep 12, 2024 · In a Phase 3 clinical trial, 99.9% of participants who took a twice-a-year injection of lenacapavir for HIV prevention did not acquire an infection, according to data from drugmaker Gilead...
New HIV drug can only offer hope of ending AIDS if all have …
WEBGENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.
Long-acting injectable lenacapavir proves effective in HIV …
WEBJul 26, 2024 · WHO welcomes the news that long-acting injectable lenacapavir as pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition in women. This represents a significant breakthrough in HIV prevention. The full results of the PURPOSE 1 trial, presented at the 25th International AIDS Conference, demonstrate the safety and ...
Full Efficacy and Safety Results for Gilead Investigational Twice ...
WEBJul 24, 2024 · Detailed data from the trial’s interim analysis announced in June showed that lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor, demonstrated zero infections, 100% efficacy and superiority to background HIV incidence for the investigational use of HIV prevention in cisgender women (women assigned female at birth).
Gilead Lenacapavir cut HIV infections by 96% in trial
WEBSep 12, 2024 · A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug. Gilead 's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The ...
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced …
WEBSep 12, 2024 · FOSTER CITY, Calif., September 12, 2024 -- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial...
- Some results have been removed